- 4,789
- 3,854
http://www.nejm.org/doi/full/10.1056/NEJMoa1707914#t=article
Canakinumab, a human monoclonal antibody targeting interleukin-1β, has anti-inflammatory effects. These effects were used to establish a new venue for interventions against second heart attacks ( cardiovascular events): controlling the inflammatory response to prevent them.
The four year study saw a 15% reduction in cardiovascular events in a patient test population of ~10000 persons worldwide who had already had a heart attack, and who had elevated CRP levels. C-reactive protein (CRP) is a precursor in the bio pathway to interleukin-1β.
A noted side effect was increased rates of infection, since inflammation is also involved in the control of infections.
See:
http://www.sciencemag.org/news/2017/08/anti-inflammatory-cuts-risk-heart-attack
For a more popular science
Canakinumab, a human monoclonal antibody targeting interleukin-1β, has anti-inflammatory effects. These effects were used to establish a new venue for interventions against second heart attacks ( cardiovascular events): controlling the inflammatory response to prevent them.
The four year study saw a 15% reduction in cardiovascular events in a patient test population of ~10000 persons worldwide who had already had a heart attack, and who had elevated CRP levels. C-reactive protein (CRP) is a precursor in the bio pathway to interleukin-1β.
A noted side effect was increased rates of infection, since inflammation is also involved in the control of infections.
See:
http://www.sciencemag.org/news/2017/08/anti-inflammatory-cuts-risk-heart-attack
For a more popular science